Advisory Center
News about Immunochina
-
IM19 Clinical Trial Started 07-072020
-
Immunochina and Edigene announce that they will jointly develop an allogeneic CAR-T therapy for cancer 05-272020
-
Immunochina obtained approval of clinical trial for IM19 CAR-T cells treatment for refractory or relapse acute B-cell lymphoblastic leukemia 04-212020
-
Immunochina obtained approval of clinical trial for IM19 CAR-T cells treatment for refractory or relapse non-Hodgkin’s lymphoma 04-152020
-
Immunochina and Peking University Cancer Hospital participated in the ESMO 2019 annual meeting and showcased the latest progress in CAR-T research 10-022019
